[vc_row][vc_column][vc_column_text css_animation=”fadeInDown”]

Check out today’s Analyst Coverage on Immunomedics, Inc. an Match Group, Inc.

[/vc_column_text][vc_raw_html]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[/vc_raw_html][vc_column_text]Immunomedics, Inc. (NASDAQ:IMMU) shares were trading higher by 0.39 percent ($0.03) at $9.03 a piece in Tuesday’s session. It had closed the previous session at $9. IMMU trades with a P/S ratio of 444.34. This compares with the industry’s 100.97 and the wider sector’s 5.64. A low price-to-sales ratio, typically less than 1.0, is considered a good value. . Shares of IMMU have downtrended -23.37% in the past three months. Immunomedics, Inc. (IMMU) has a market cap of $1.33 billion and over the last 12 months, Immunomedics, Inc. (NASDAQ:IMMU) has gone stronger by 175.46%. During the last 52 weeks, the (NASDAQ:IMMU) price has been as high as $14.48 and as low as $3.16. Immunomedics, Inc. earnings have declined with an annualized rate of -44.67% over the last 5 years.

Immunomedics, Inc. (Mean Target Price: $15)

The average 1-year price target for Immunomedics, Inc. (IMMU) — averaging the work of different analysts — reveals a mean PT of $15/share. That’s a potential 66.11 increase relative to where Immunomedics, Inc. (NASDAQ:IMMU) has been trading recently. The current price is seen ranging between $8.68 and $9.38. There are brokerage firms with lower targets than the average, including one setting a price target of $14. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $16.

Immunomedics, Inc. (IMMU) Consensus Recommendation

The collective rating of 1.3 for Immunomedics, Inc. (NASDAQ:IMMU) also leans strongly towards the bullish end of the spectrum. Of the 3 analysts surveyed by Reuters that track IMMU 0 of them rate its stock a hold. The other 3, though not evenly; between analysts who think you should buy Immunomedics, Inc. versus those who think you should sell it. A 3 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of IMMU or, if they already own its stock, sell it.

Is Match Group, Inc. (NASDAQ:MTCH) Cheap From Peers?

Match Group, Inc. (MTCH) pulled off a 0.39 percent gain and now trades for $28.33. MTCH comes in with a P/S ratio of 6.02 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (2.67) and its peers (6.86). Also, it has an estimated price-earnings (P/E) multiple of 25.73 and a trailing 12-month price-earnings (P/E) multiple of 18.84. During the last 52 weeks, the price has been as high as $32.87 and as low as $15.42. Match Group, Inc. (NASDAQ:MTCH) earnings have declined with a quarterly rate of 0% over the last 5 years. Shares of MTCH have increased 21.74% in the past three monthswhile the S&P 500 has gained 18.47% in that time.

Match Group, Inc. (Price Objective: $32.67)

Match Group, Inc. (NASDAQ:MTCH) has a market cap of $7.65 billion and over the last 12 months, MTCH has risen by 61.33%. The average 1-year price target for (MTCH) reveals an average price target of $32.67 per share. That’s a potential 15.32 gain from where (NASDAQ:MTCH) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $25. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $35.

Analyst Thoughts About Match Group, Inc. (NASDAQ:MTCH)

The consensus recommendation — averaging the work of 17 analysts — of 2.1 for Match Group, Inc. (MTCH) points to moderate case. Of the analysts surveyed by Reuters that track Match Group, Inc. 6 of them rate its stock a hold. The other 11 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 11 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NASDAQ:MTCH) or, if they already own its stock, sell it.[/vc_column_text][/vc_column][/vc_row]